HEMS MEDICATION SECTION

Furosemide (INTERFACILITY TRANSFER)

Date: June 9, 2022 Section: 9-51

Furosemide Interfacility Transfer

Indications:

Interfacility transport of a patient with volume overload and edema caused by conditions such as heart failure, liver disease, and kidney disease. Furosemide IV is initiated at the transferring facility and may be continued during transport by an ALS unit staffed with a Paramedic current with Expanded Scope of Practice training. This treatment is not to be initiated by the Expanded Scope of Practice Trained paramedic independently.

Contraindications:

Sensitivity to Furosemide and patients with anuria

Typical Sending Facility Administration:

Maintain drip per sending facility orders.

Procedure:

Maintain appropriate delivery rate by IV infusion pump.

Continuous cardiac monitoring, monitor vital signs every 10 minutes.

Adverse Effects:

Headache, dizziness, muscle cramps, orthostatic hypotension

If patient develops adverse reaction contact medical control from sending facility.

**Not in Medication Box

MCA Name: HEMS, Inc. (WW/DR)
MCA Board Approval Date: 2/8/2024

MCA Implementation Date: 3/1/2024

MDHHS Approval:

Page 1 of 1